Valuation: Biotron Limited

Market Cap 5.57M 3.97M 3.44M 3.25M 2.95M 5.53M 381M 38.83M 14.94M 193M 14.92M 14.59M 616M P/E 2025
-6.29x
P/E 2026 -4.1x
Enterprise Value 4.02M 2.86M 2.48M 2.35M 2.12M 3.99M 275M 28M 10.77M 139M 10.76M 10.52M 444M EV / Sales 2025
0.95x
EV / Sales 2026 12.5x
Free-Float
73.16%
Yield 2025 *
-
Yield 2026 -
6 months-20.00%
Current year-33.33%
1 week 0
Extreme 0.002
0
1 month 0
Extreme 0.002
0
Current year 0
Extreme 0.001
0
1 year 0
Extreme 0.001
0
3 years 0
Extreme 0.001
0.12
5 years 0
Extreme 0.001
0.12
10 years 0
Extreme 0.001
0.44
Manager TitleAgeSince
Corporate Secretary 62 2025-05-01
Director TitleAgeSince
Director/Board Member - 2012-03-06
Director/Board Member - 2018-10-22
Director/Board Member - 2025-07-15
Date Insider Type Main position Quantity % Market Cap. Importance
11/28/24 Expiration

Chief Executive Officer

165,000 0.0183%
11/28/24 Expiration

Director

268,403 0.0297%
11/28/24 Expiration

Chairman

934,780 0.1036%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-42.86%-93.94% 3.97M
-1.38%+0.20%+46.42%+96.33% 69.18B
-0.75%-1.46%+35.20%+74.64% 62B
-4.29%-3.98%-16.22%+350.66% 26.19B
+1.46%+2.25%+28.84%+14.54% 25.75B
-2.20%-2.00%-1.22%-14.48% 24.29B
+3.09%+3.94%+24.99%-14.79% 19.84B
+1.26%-14.23%+170.04%+298.75% 15.65B
-5.54%+0.69%-8.13%+830.48% 13.88B
-0.39%-4.24%-9.86%+454.94% 14.09B
Average -0.87%-1.98%+22.72%+199.71% 27.09B
Weighted average by Cap. -1.00%-1.32%+31.71%+158.07%

Financials

2025 2026
Net sales 1.81M 1.29M 1.12M 1.06M 959K 1.8M 124M 12.64M 4.86M 62.91M 4.86M 4.75M 201M 526K 375K 325K 307K 278K 522K 35.97M 3.67M 1.41M 18.24M 1.41M 1.38M 58.17M
Net income -319K -227K -197K -186K -168K -316K -21.79M -2.22M -854K -11.05M -853K -834K -35.24M -1.52M -1.08M -938K -887K -803K -1.51M -104M -10.58M -4.07M -52.67M -4.07M -3.98M -168M
Net Debt -932K -664K -576K -544K -493K -925K -63.74M -6.49M -2.5M -32.32M -2.5M -2.44M -103M -1.55M -1.11M -960K -908K -822K -1.54M -106M -10.83M -4.17M -53.9M -4.16M -4.07M -172M
Logo Biotron Limited
Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in developing and commercializing a novel small molecule approach that has the potential to treat several serious viral diseases. Its proprietary primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins, including hepatitis C, HIV-1, Dengue, Zika, Influenza, and Respiratory Syncytial Virus (RSV). The Company has developed a library of over 350 compounds with potential activity against a range of viral diseases. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. BIT225 appears to inhibit HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. The Company also owns SedRx, which is a general anesthetic containing alfaxalone.
Employees
3
Date Price Change Volume
26-09-15 A$0.002000 0.00% 761,201
26-09-14 A$0.002000 0.00% 100,000
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!